文献速递毛发、甲与色素性疾病

可溶性CD83通过IDO介导的Treg激活逆转斑秃

Soluble CD83 reverses alopecia areata via indoleamine 2,3-dioxygenase-mediated regulatory T cell activation.
PubMed 文献 · Br J Dermatol · 2026-01-01

斑秃患者存在可溶性CD83(sCD83)缺陷,血清sCD83水平与疾病严重程度负相关。在斑秃小鼠模型中补充sCD83可逆转疾病表现并促进Treg增殖,其机制依赖毛囊外根鞘角质形成细胞的IDO活性,硫氧还蛋白可能作为sCD83受体调控IDO表达。

要点

  • 斑秃患者sCD83水平降低且与病情严重度负相关
  • 补充sCD83可逆转小鼠斑秃并促进Treg增殖
  • sCD83经IDO依赖途径激活Treg,硫氧还蛋白可能为其受体

核心结论

  • sCD83在斑秃中发挥功能作用,补充sCD83具有治疗潜力。

研究设计与样本

  • 收集斑秃患者与健康对照的外周血和头皮组织,用ELISA、流式细胞术和免疫荧光检测sCD83。
  • 采用移植诱导的C3H/HeJ斑秃小鼠模型评估sCD83对早期斑秃的治疗效果。
  • 体外使用人毛囊器官培养和原代外根鞘角质形成细胞培养,结合IDO抑制剂和共培养实验验证机制。

主要发现

  • 斑秃患者存在sCD83缺陷,可能归因于树突状细胞释放sCD83减少。
  • 血清sCD83水平与疾病严重程度呈负相关。
  • 在斑秃小鼠模型中补充sCD83可逆转疾病表现并促进Treg增殖。
  • 外根鞘角质形成细胞中的IDO活性对sCD83介导的Treg激活至关重要。
  • 硫氧还蛋白可能作为sCD83受体调控IDO表达。

关键数值与推荐

  • 斑秃患者sCD83水平降低,血清sCD83水平与疾病严重程度负相关。
  • 补充sCD83可逆转斑秃小鼠模型疾病表现并促进Treg增殖。
  • IDO活性是sCD83介导Treg激活所必需,硫氧还蛋白可能为sCD83受体。

临床怎么用

  • sCD83补充可能成为斑秃的潜在治疗方法。
  • 检测sCD83水平可能作为斑秃的诊断方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary cause of alopecia areata (AA) is autoimmune-mediated hair follicle destruction, while breakdown of immune tolerance due to disruption of regulatory T cell (Treg) homeostasis critically contributes to this process. However, the factors leading to impairment of Tregs and the effective regulatory pathways in AA remain unclear. OBJECTIVES: To assess the therapeutic effects of soluble CD83 (sCD83) on AA and elucidate the crucial role of sCD83-mediated Treg activation in remodelling the perifollicular microenvironment. METHODS: Blood and scalp tissue were collected from patients with AA and healthy control participants to characterize sCD83 using enzyme-linked immunosorbent assay, flow cytometry and immunofluorescence. Using a graft-induced C3H/HeJ mouse model of AA, the therapeutic effect of sCD83 on early-onset AA was evaluated by haematoxylin and eosin staining, immunofluorescence and flow cytometry. In vitro, human hair follicle organ culture and primary outer root sheath keratinocyte (ORSK) culture were used to clarify the impact of sCD83 on the expression and activity of indoleamine 2,3-dioxygenase (IDO) in hair follicles. Co-culture of ORSKs and peripheral blood mononuclear cells, together with administration of an IDO inhibitor to AA mice, were performed to determine the necessity of IDO for Treg activation. Finally, glutathione S-transferase-pulldown and co-immunoprecipitation assays were used to identify potential sCD83 receptors on ORSKs. RESULTS: We showed here that patients with AA exhibit sCD83 deficiency, which may be attributed to reduced sCD83 release from dendritic cells, and that serum sCD83 levels are negatively correlated with disease severity. Supplementation with sCD83 in an AA mouse model reversed disease manifestations and promoted Treg proliferation. Mechanistically, IDO activity in ORSKs is essential for sCD83-mediated Treg activation, with thioredoxin potentially serving as an sCD83 receptor to regulate IDO expression. CONCLUSIONS: Our study establishes the functional role of sCD83 in AA, confirms the therapeutic potential of sCD83 supplementation and provides some mechanistic insights. Alopecia areata (pronounced al-oh-pee-sha ar-ee-a-tah) affects approximately 2% of people globally. It causes sudden, patchy hair loss on the scalp and body. Each hair strand is anchored to the skin within a ‘tunnel-like’ pocket called a hair follicle. In alopecia areata, the immune system mistakenly attacks itself around the hair follicle. The attack causes a form of localized inflammation. The cells that control this immune activity are called regulatory T cells (Tregs). These appear small and/or damaged within alopecia areata patches. CD83 is a protein that spans the entire outer boundary of a cell. It can shed part of itself into bodily fluids to create a soluble form, called sCD83. sCD83 can suppress immune activity. In this study, we looked at samples collected from scalp and blood samples of people with alopecia areata. These were compared to samples from people without alopecia areata. We found that people with alopecia areata had much lower levels of sCD83. Also, the lower the level, the more severe the alopecia areata seemed to be. Further tests determined that sCD83 can ‘wake up’ Tregs around hair follicles. This can help to rebalance the immune system and promote hair regeneration. During this process, a protein called indoleamine 2,3-dioxygenase plays an important role. Our study highlights how sCD83’s effects on Tregs can improve the microenvironment of hair follicles in alopecia areata. sCD83 supplementation could be a potential treatment for alopecia areata. Identifying low levels of sCD83 could also provide a method for diagnosis of alopecia areata.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan S, Li Y, Liu X, et al. Soluble CD83 reverses alopecia areata via indoleamine 2,3-dioxygenase-mediated regulatory T cell activation. Br J Dermatol. 2026. PMID: 42397957. doi:10.1093/bjd/ljag274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。